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1. INTRODUCTION {#jgf2269-sec-0001}
===============

Ceftriaxone is a third‐generation cephalosporin that is widely used for various infectious diseases, such as respiratory tract and gastrointestinal tract infections and meningitis. Schaad et al first reported ceftriaxone‐associated pseudolithiasis in 1986,[1](#jgf2269-bib-0001){ref-type="ref"} and both adult and pediatric cases have been reported recently. Obesity, fatty diet, aging, pregnancy, oral contraceptive, gallbladder dysfunction due to fasting, high dose of ceftriaxone, low albumin, and kidney disease have been reported as factors contributing to gallbladder stone formation.[2](#jgf2269-bib-0002){ref-type="ref"} Pseudolithiasis after ceftriaxone initiation is thought to be one of the side effects, but few reports have described asymptomatic presentations.

2. CASE {#jgf2269-sec-0002}
=======

An 88‐year‐old woman with a history of meningioma and dementia was admitted with high fever, appetite loss, nausea, and weight loss in July. Urinalysis showed increased white blood cells and presence of nitrite, and urinary tract infection was suspected. Computed tomography (CT) showed no significant findings (Figure [1](#jgf2269-fig-0001){ref-type="fig"}A). Ceftriaxone was administered at 2 g/d, and urinary findings improved after 14 days. However, inappetence continued. We discussed with the patient and her family the possibility of providing nutrition by percutaneous endoscopic gastrostomy (PEG), and consent was provided. On hospital day 20, PEG was successfully implemented. We initiated tube feeding by PEG, and her condition remained stable. However, high fever developed on hospital day 28. Urinary tests showed normal results, but C‐reactive protein was increased (5.8 mg/dL) in blood tests. CT identified a gallbladder stone (Figure [1](#jgf2269-fig-0001){ref-type="fig"}B), but the patient reported no abdominal symptoms. We considered viral or bacterial infection as a potential cause of high fever. In terms of the gallbladder stone on CT, we considered the possibility of ceftriaxone‐associated pseudolithiasis and changed pharmacotherapy to cefmetazole for the bacterial infection. Her general condition improved, and CT on hospital day 34 showed a reduction in the size of the gallbladder stone (Figure [1](#jgf2269-fig-0001){ref-type="fig"}C). She was discharged on hospital day 47.

![A, Abdominal CT on admission shows no gallbladder stone. B, Abdominal CT on hospital day 28 (during ceftriaxone treatment) clearly shows a gallbladder stone (arrowhead). C, CT on hospital day 34 (after discontinuation of ceftriaxone) shows a reduction in size of the gallbladder stone](JGF2-20-209-g001){#jgf2269-fig-0001}

3. DISCUSSION {#jgf2269-sec-0003}
=============

This case suggests an important clinical issue. Ceftriaxone is a broad‐spectrum, third‐generation cephalosporin used to treat various infectious diseases. Ceftriaxone is 85%‐95% bound to albumin in blood, with 60% excreted unchanged in urine and 40% in bile. As a result, ceftriaxone concentration in bile is 20 to 150 times that in serum.[3](#jgf2269-bib-0003){ref-type="ref"} High‐concentration ceftriaxone inhibits bile acid excretion, and calcium ions in bile are increased. Ceftriaxone shows high affinity to calcium ions and produces a biliary sludge comprising the calcium salt of ceftriaxone.[3](#jgf2269-bib-0003){ref-type="ref"}

The first issue to consider in association with this case is that asymptomatic gallbladder stones can form when using ceftriaxone. The incidence of pseudolithiasis has been reported as between 10.1% and 57.5%[4](#jgf2269-bib-0004){ref-type="ref"}, [5](#jgf2269-bib-0005){ref-type="ref"}, [6](#jgf2269-bib-0006){ref-type="ref"}, [7](#jgf2269-bib-0007){ref-type="ref"}, and symptoms occur in a minority of patients (0%‐19%).[4](#jgf2269-bib-0004){ref-type="ref"}, [8](#jgf2269-bib-0008){ref-type="ref"}, [9](#jgf2269-bib-0009){ref-type="ref"} Our patient also had no abdominal symptoms, with the gallbladder stone only found incidentally on CT. Thus, even though ceftriaxone‐associated pseudolithiasis can occur, many patients may show no symptoms, so clinician should pay careful attention to this possibility when using ceftriaxone.

Second, patients who have a complicated background may be at greater risk of ceftriaxone‐associated pseudolithiasis. Case reports from Japan of ceftriaxone‐associated pseudolithiasis in adults are shown in Table [1](#jgf2269-tbl-0001){ref-type="table"}.[10](#jgf2269-bib-0010){ref-type="ref"}, [11](#jgf2269-bib-0011){ref-type="ref"}, [12](#jgf2269-bib-0012){ref-type="ref"}, [13](#jgf2269-bib-0013){ref-type="ref"}, [14](#jgf2269-bib-0014){ref-type="ref"}, [15](#jgf2269-bib-0015){ref-type="ref"}, [16](#jgf2269-bib-0016){ref-type="ref"}, [17](#jgf2269-bib-0017){ref-type="ref"}, [18](#jgf2269-bib-0018){ref-type="ref"}, [19](#jgf2269-bib-0019){ref-type="ref"}, [20](#jgf2269-bib-0020){ref-type="ref"}, [21](#jgf2269-bib-0021){ref-type="ref"}, [22](#jgf2269-bib-0022){ref-type="ref"}, [23](#jgf2269-bib-0023){ref-type="ref"}, [24](#jgf2269-bib-0024){ref-type="ref"} These patients have shown various underlying conditions, and most patients have been elderly. The clinical course after the diagnosis of ceftriaxone‐associated pseudolithiasis is usually good following conservative therapy. However, very elderly patients often have several underlying diseases and tend to be dehydrated, increasing the susceptibility to ceftriaxone‐associated pseudolithiasis, so careful treatment is needed. Japan has an aging society, and increasing use of ceftriaxone with the growing burden of infectious disease is expected. Patients with dementia, relative inactivity, dysfunction of the gastrointestinal tract, and a long‐term bedridden state might be at greater risk of asymptomatic gallbladder stone formation when using ceftriaxone.

###### 

Reported cases of ceftriaxone‐associated pseudolithiasis in Japan

  Year   Author                                               Age   Gender   Infection type               Underlying disease                                                           Dose (g)   Duration   Abdominal symptom   Course                         Time to disappearance   Outcome
  ------ ---------------------------------------------------- ----- -------- ---------------------------- ---------------------------------------------------------------------------- ---------- ---------- ------------------- ------------------------------ ----------------------- -----------------
  2009   Sasaki [10](#jgf2269-bib-0010){ref-type="ref"}       35    F        Colon diverticulitis         none                                                                         2          13 d       epigastralgia       EST/ERBD                       2 mo                    EST/ERBD
  2009   Tsuzaki [11](#jgf2269-bib-0011){ref-type="ref"}      24    M        Endocarditis                 none                                                                         2, 4       46 d       hypochondralgia     Cholecystectomy                82 d                    Cholecystectomy
  2012   Nakagawara [12](#jgf2269-bib-0012){ref-type="ref"}   65    M        Enteritis                    Diabetes, hypertension                                                       2          7 d        none                EST                            15 d                    EST
  2013   Tomoda [13](#jgf2269-bib-0013){ref-type="ref"}       47    F        Colon diverticulitis         none                                                                         2          8 d        none                CTRX stop                      6 d                     Disappearance
  2013   Imoto [14](#jgf2269-bib-0014){ref-type="ref"}        66    M        Meningitis                   Diabetes, renal failure                                                      4          22 d       none                ERBD                           21 d                    ERBD
  2013   Imoto [14](#jgf2269-bib-0014){ref-type="ref"}        67    M        Meningitis                   Hypertension, dyslipidemia                                                   4          23 d       none                CTRX stop                      42 d                    disappearance
  2015   Tanaka [15](#jgf2269-bib-0015){ref-type="ref"}       83    F        Renal Abscess                Hypertension                                                                 2          36 d       epigastralgia       Cholecystectomy                Unknown                 Cholecystectomy
  2015   Shima [16](#jgf2269-bib-0016){ref-type="ref"}        79    F        Bronchial Pneumonia          Renal failure                                                                1          13 d       stomachache         CTRX stop                      48 d                    disappearance
  2016   Dohmen [17](#jgf2269-bib-0017){ref-type="ref"}       76    M        Pneumonia                    Hypertension, dyslipidemia, diabetes                                         2          8 d        Abdominal pain      Change to another antibiotic   22 d                    Disappearance
  2016   Niwa [18](#jgf2269-bib-0018){ref-type="ref"}         23    F        Colon diverticulitis         none                                                                         2          6 d        epigastralgia       Change to another antibiotic   1 mo                    Disappearance
  2016   Niwa [18](#jgf2269-bib-0018){ref-type="ref"}         76    F        Subcutaneous abscess         none                                                                         2          8 d        hypochondralgia     Change to another antibiotic   1 mo                    Disappearance
  2016   Niwa [18](#jgf2269-bib-0018){ref-type="ref"}         63    M        Hepatic abscess              Diabetes, lung cancer, colon cancer                                          3, 4       20 d       none                Change to another antibiotic   2 mo                    Disappearance
  2016   Niwa [18](#jgf2269-bib-0018){ref-type="ref"}         93    M        Pneumonia                    Brain infarction (hemiplegia)                                                2          7 d        hypochondralgia     Change to another antibiotic   Unknown                 Disappearance
  2017   Tsukagoshi [19](#jgf2269-bib-0019){ref-type="ref"}   70    M        Brain abscess                ANCA‐associated vasculitis                                                   4          14 d       none                CTRX stop                      14 d                    Disappearance
  2017   Tsukagoshi [19](#jgf2269-bib-0019){ref-type="ref"}   39    M        Meningitis                   none                                                                         4          7 wk       none                CTRX stop                      2 wk                    Reduction
  2017   Tsukagoshi [19](#jgf2269-bib-0019){ref-type="ref"}   35    M        Brain abscess                Myasthenia gravis                                                            4          2 wk       none                CTRX stop                      5 wk                    Resolved
  2017   Doi [20](#jgf2269-bib-0020){ref-type="ref"}          91    F        Pulmonary edema, Pneumonia   Renal failure, hypertension, glomerulonephritis                              2          10 d       Abdominal pain      ERBD                           4 wk                    ERBD
  2017   Doi [20](#jgf2269-bib-0020){ref-type="ref"}          82    F        Acute enteritis              Dermatomyositis, interstitial pneumonitis, diabetes, chronic heart failure   2          5 d        Abdominal pain      EST ERBD,                      Unknown                 Died
  2017   Abe [21](#jgf2269-bib-0021){ref-type="ref"}          89    F        Pneumonia                    End‐stage renal disease                                                      1          7 d        epigastralgia       Change to another antibiotic   Unknown                 Died
  2018   Nakagawa [22](#jgf2269-bib-0022){ref-type="ref"}     74    M        Bronchial pneumonia          Lung cancer                                                                  2          5 d        epigastralgia       ERCP                           Unknown                 ERCP
  2018   Murata [23](#jgf2269-bib-0023){ref-type="ref"}       85    M        Acute enteritis              Lung cancer                                                                  ‐          8 d        hypochondralgia     Cholecystectomy                22 d                    Cholecystectomy
  2018   Ishikawa [24](#jgf2269-bib-0024){ref-type="ref"}     78    F        Ischemia colitis             Hypertension, chronic kidney disease, diabetes                               ‐          8 d        none                CTRX stop                      41 d                    Disappearance
  2018   Ishikawa [24](#jgf2269-bib-0024){ref-type="ref"}     84    M        Pneumonia                    none                                                                         1          17 d       none                CTRX stop                      Unknown                 Unknown
  2018   Our case                                             88    F        Urinary infection            Dementia, brain tumor (hemiplegia), bedridden state                          2          14 d       none                Change to another antibiotic   34 d                    Reduction

Abbreviations: CTRX, ceftriaxone; ERBD, endoscopic retrograde biliary drainage; ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy.
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Third, the summer season might be a risk factor for ceftriaxone‐associated pseudolithiasis. A past report[25](#jgf2269-bib-0025){ref-type="ref"} showed that high environmental temperatures may represent an important risk factor for pseudolithiasis in children. In Japan, high temperature is common throughout summer and may induce a loss of body fluids, promoting sludge formation. Closer attention to meteorological conditions may thus be warranted.

In conclusion, ceftriaxone‐associated pseudolithiasis might arise in the absence of abdominal symptoms, and clinicians should take into account the patient background and season when determining the dose and duration of use for this agent.
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